- €897.31m
- €513.16m
- €535.18m
Brief: Curevac Initiates Strategic Restructuring
GSK buys full rights to make COVID, influenza vaccines from CureVac
Brief: Curevac Announces Dosing Of First Participant In A Phase 2 Study In Seasonal Influenza
Brief: CureVac Says Organizational Redesign On Track
Moderna shares jump, set for eight straight day of gains
Acuitas, CureVac settle lawsuit over COVID-19 vaccine patent rights
Brief: Curevac Q4 Net Financial Result At EUR 1.5 Mln
Brief: CureVac: Start Of Combined Phase 1/2 Study In Avian Influenza
Brief: Curevac And MD Anderson To Cooperate On Developing Novel Cancer Vaccines
Brief: Curevac Announces Phase 2 Interim Data From Seasonal Influenza Vaccine Development Program In Collaboration With GSK
Brief: Curevac NV CEO Alexander Zehnder Purchased 50,000 Common Shares Of Curevac Stock
CureVac rises on data from COVID-19 vaccine development program with GSK
Brief: Curevac: Positive Phase 2 Interim Data From Covid-19 Vaccine Development Program
Brief: Curevac Announces Decision In Patent Litigation With Biontech By German Federal Patent Court
CureVac slumps as German court quashes patent after challenge by BioNTech
Brief: Curevac: To Appeal Patent Decision Before German Federal Court Of Justice
German court quashes CureVac patent after challenge by BioNTech (updated)
German court quashes CureVac patent after challenge by BioNTech
Factbox: German government holdings in companies